- Home
- ANAB vs INN Comparison
ANAB vs INN Comparison
Compare ANAB & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- INN
- Stock Information
- Founded
- ANAB 2005
- INN 2010
- Country
- ANAB United States
- INN United States
- Employees
- ANAB N/A
- INN N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- INN Real Estate Investment Trusts
- Sector
- ANAB Health Care
- INN Real Estate
- Exchange
- ANAB Nasdaq
- INN Nasdaq
- Market Cap
- ANAB 621.1M
- INN 573.5M
- IPO Year
- ANAB 2017
- INN 2011
- Fundamental
- Price
- ANAB $20.14
- INN $5.22
- Analyst Decision
- ANAB Buy
- INN Hold
- Analyst Count
- ANAB 10
- INN 1
- Target Price
- ANAB $48.00
- INN $5.75
- AVG Volume (30 Days)
- ANAB 500.2K
- INN 856.2K
- Earning Date
- ANAB 08-06-2025
- INN 08-05-2025
- Dividend Yield
- ANAB N/A
- INN 6.09%
- EPS Growth
- ANAB N/A
- INN N/A
- EPS
- ANAB N/A
- INN N/A
- Revenue
- ANAB $123,164,000.00
- INN $727,133,000.00
- Revenue This Year
- ANAB N/A
- INN $2.58
- Revenue Next Year
- ANAB $24.39
- INN $2.29
- P/E Ratio
- ANAB N/A
- INN N/A
- Revenue Growth
- ANAB 304.17
- INN N/A
- 52 Week Low
- ANAB $12.21
- INN $3.57
- 52 Week High
- ANAB $40.70
- INN $7.22
- Technical
- Relative Strength Index (RSI)
- ANAB 31.39
- INN 48.64
- Support Level
- ANAB $19.55
- INN $4.97
- Resistance Level
- ANAB $22.03
- INN $5.63
- Average True Range (ATR)
- ANAB 1.50
- INN 0.22
- MACD
- ANAB -0.53
- INN 0.00
- Stochastic Oscillator
- ANAB 12.05
- INN 59.31
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About INN Summit Hotel Properties Inc.
Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The firm's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.